Suppr超能文献

炎症性肠病中的粪便微生物移植:一个不容忽视的大趋势。

Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be Ignored.

机构信息

Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.

Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), Edmonton, Alberta, Canada.

出版信息

Clin Pharmacol Ther. 2017 Oct;102(4):588-590. doi: 10.1002/cpt.747. Epub 2017 Jul 10.

Abstract

The development of new therapies for inflammatory bowel disease is plagued by high costs, potential side effects, and variable levels of effectiveness. Fecal microbial transplant in inflammatory bowel diseases can offer an alternative to traditionally developed pharmacologic therapies and has demonstrated the ability to induce disease remission in randomized control trials. However, questions remain about the ultimate role of this therapy in disease management, including long term safety, and the optimal composition of transplanted stool.

摘要

炎症性肠病新疗法的开发受到高成本、潜在副作用和疗效差异的困扰。在炎症性肠病中,粪便微生物移植可以替代传统开发的药物治疗,并已在随机对照试验中证明能够诱导疾病缓解。然而,关于这种治疗在疾病管理中的最终作用,包括长期安全性和移植粪便的最佳组成,仍存在一些问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验